Scholar Rock is trading at $47.35, up 4.07%, with the move appearing linked to broader biotech-sector strength rather than a company-specific catalyst.
- Moderna raised its 2026 revenue-growth outlook to 15%β25% after strong results, supporting broader biotech sentiment.
- Scholar Rockβs next quarterly results are scheduled for November 10.
- Volume or unusual trading activity was not established.